CD44 and non-small cell lung carcinoma: Moreover, the review examines the advantages, challenges, and potential outcomes of using CD44-targeted nanocarriers for NSCLC therapy, aiming to provide information and direction for the advancement of groundbreaking and efficient treatment approaches for this formidable ailment.